Trials / Conditions / Ovarian Cancer Stage IV

Ovarian Cancer Stage IV

27 registered clinical trials studyying Ovarian Cancer Stage IV — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NCT05479045	Georgetown University	Phase 2
Recruiting	Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer NCT07067255	Essen Biotech	Phase 1 / Phase 2
Not Yet Recruiting	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study NCT06650709	British Columbia Cancer Agency	Phase 2
Recruiting	Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy NCT06268665	University of California, Davis	Phase 2
Recruiting	Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Tumor Microenvironment in Ovarian Cancer NCT06272240	University of Udine	—
Recruiting	Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer NCT06017557	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	N/A
Recruiting	Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer NCT04701645	Brigham and Women's Hospital	Phase 1
Unknown	Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments NCT06025045	Jing Li	—
Recruiting	Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving NCT04997096	Dana-Farber Cancer Institute	N/A
Unknown	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer NCT05187208	Seoul National University Hospital	Phase 4
Completed	Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy NCT05005650	Seoul National University Hospital	—
Active Not Recruiting	Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian C NCT04938583	CanariaBio Inc.	Phase 1 / Phase 2
Recruiting	Prehabilitation in Gynaecological Cancer Patients NCT04789694	Charles University, Czech Republic	Phase 3
Unknown	A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ova NCT03899610	Yonsei University	Phase 2
Terminated	Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Canc NCT03922776	Centre Oscar Lambret	N/A
Unknown	Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Periton NCT03693248	Seoul National University Hospital	Phase 3
Completed	Self-Advocacy Serious Game in Advanced Cancer NCT03339765	University of Pittsburgh	N/A
Completed	Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer NCT03579394	ARCAGY/ GINECO GROUP	N/A
Completed	PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . NCT03275506	ARCAGY/ GINECO GROUP	Phase 2
Completed	Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer NCT03126812	The Netherlands Cancer Institute	Phase 1 / Phase 2
Completed	PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer NCT03304210	University Hospital, Ghent	Phase 1
Terminated	The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian NCT03162562	CanariaBio Inc.	Phase 1
Completed	To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumo NCT03159585	Zhujiang Hospital	Phase 1
Completed	Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer NCT03085238	MTrap, Inc.	N/A
Completed	Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer NCT02258165	Queensland Centre for Gynaecological Cancer	—
Completed	Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer NCT00945191	Daiichi Sankyo	Phase 2